Listing of the Claims

1. (Currently amended) A method of treating a mammal suffering from prostate or breast cancer, the method comprising administering to the mammal a therapeutically effective amount of a compound of the general formula (I)



(I)

wherein

R^1, R^2, R^3, and R^4 independently are selected from hydrogen, optionally substituted C_{1-6}-alkyl, ~~optionally substituted C_{2-6} alkenyl, hydroxyl, optionally substituted C_{1-6} alkoxy, optionally substituted C_{2-6} alkenyloxy, carboxy, optionally substituted C_{1-6} alkoxycarbonyl, optionally substituted C_{1-6} alkylcarbonyl, optionally substituted C_{1-6} alkylcarbonyloxy, formyl, amino, mono- and di(C_{1-6} alkyl)amino, carbamoyl, mono- and di(C_{1-6}-alkyl)aminocarbonyl, C_{1-6} alkylcarbonylamino, C_{1-6}-alkylsuphonylamino, cyano, carbamido, mono- and di(C_{1-6}-alkyl)aminocarbonylamino, C_{1-6}-alkanoyloxy, C_{1-6}-alkylsulphonyl, C_{1-6}-alkylsulphinyl, aminosulfinyl, mono- and di(C_{1-6} alkyl)aminosulfonyl, nitro, optionally substituted C_{1-6}-alkylthio, aryl, aryloxy, arylcarbonyl, arylamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclcylcarbonyl, heteroaryl, heteroaryloxy, heteroarylamino, heteroarylcarbonyl,~~ and halogen, ~~where any C_{1-6}-alkyl as an amino substituent is optionally substituted with hydroxyl, C_{1-6}-alkoxy, amino, mono- and di(C_{1-6}-alkyl)amino, carboxy, C_{1-6}-~~

~~alkylcarbonylamino, C_{1-6}-alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocycyl and heteroaryl may e optionally substituted;~~

~~or R^1 and R^2 together with the carbon atoms to which they are attached form a ring;~~

with the proviso that R^1, R^2, R^3 and R^4 are not all hydrogen;

X^1 and X^2 are independently selected from hydroxy (-OH) and acetoxy (-OAc); and

pharmaceutically acceptable salts thereof.

2-3. (Cancelled)

4. (Currently amended) The method according to claim 1, wherein R^1 is selected from hydrogen, halogen, C_{1-6}-alkyl, and trifluoromethyl ~~and C_{1-6} alkoxy~~.

5. (Currently amended) The method according to claim 1, wherein R^2 is selected from hydrogen, and halogen~~, optionally substituted aryl, optionally substituted arlyoxy, and optionally substituted heteroaryl~~.

6. (Currently amended) The method according to claim 1, wherein R^3 is selected from hydrogen~~, optionally substituted C_{1-6} alkoxy,~~ and halogen~~, cyano, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, amino, C_{1-6}-alkylcarbonylamino, C_{1-6}-alkylsulphonylamino, and mono- and di(C_{1-6}-alkyl)aminosulfonyl~~.

7. (Previously presented) The method according to claim 1, wherein R^4 is hydrogen.

8-20. (Cancelled)

21. (Currently amended) The method according to claim 1, wherein R^1 is selected from fluoro, chloro, bromo, C_{1-4}-alkyl, and trifluoromethyl~~, C_{1-4} alkoxy, and dimethylaminocarbonyl~~.

22. (Cancelled)

23. (Currently amended) The method according to claim 1, wherein R^1 is selected from halogen, C_{1-4}-alkyl, and trifluoromethyl~~, C_{1-4} alkoxy, and dimethylaminocarbonyl~~, R^2 is selected

from hydrogen and halogen, and R^3 is selected from hydrogen, halogen, and C_{1-4}-alkyl~~, and amino~~; where R^2 and R^3 are not both hydrogen.

24. (Currently amended) A method of treating a mammal suffering from prostate or breast cancer, the method comprising administering to the mammal a therapeutically effective amount of a 3,3-diphenyl-1,3-dihydro-indol-2-one type compound of the formula (IIa)



(IIa)

wherein

R^1 is selected from hydrogen, halogen, C_{1-6}-alkyl, and trifluoromethyl~~ and C_{1-6} alkoxy~~;

R^2 is selected from hydrogen, and halogen~~, optionally substituted aryl, optionally substituted aryloxy, and optionally substituted heteroaryl~~;

R^3 is selected from hydrogen, and ~~optionally substituted C_{1-6} alkoxy,~~ halogen~~, acyano, and optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, amino, C_{1-6}-alkylcarbonylamino, C_{1-6}-alkylsulphonylamino, and mono- and di(C_{1-6}-alkyl)aminosulfonyl~~; and

with the proviso that R^1, R^2 and R^3 are not all hydrogen;

X^1 and X^2 are independently selected from hydroxy (-OH) and acetoxy (-OAc); and

pharmaceutically acceptable salts thereof.

25. (Currently amended) A method of treating a mammal suffering from prostate or breast cancer, the method comprising administering to the mammal a therapeutically effective amount of a 3,3-diphenyl-1,3-dihydro-indol-2-one type compound of the formula (IIb)



(IIb)

wherein

R^1, R^2, and R^3 independently are selected from hydrogen, optionally substituted C_{1-6}-alkyl, ~~optionally substituted C_{2-6} alkenyl, hydroxyl, optionally substituted C_{1-6} alkoxy, optionally substituted C_{2-6} alkenyloxy, carboxy, optionally substituted C_{1-6} alkoxycarbonyl, optionally substituted C_{1-6} alkylcarbonyl, optionally substituted C_{1-6} alkylcarbonyloxy, formyl, amino, mono- and di(C_{1-6} alkyl)amino, carbamoyl, mono- and di(C_{1-6}-alkyl)aminocarbonyl, C_{1-6} alkylcarbonylamino, C_{1-6}-alkylsuphonylamino, cyano, carbamido, mono- and di(C_{1-6}-alkyl)aminocarbonylamino, C_{1-6}-alkanoyloxy, C_{1-6}-alkylsulphonyl, C_{1-6}-alkylsulphinyl, aminosulfinyl, mono- and di(C_{1-6} alkyl)aminosulfonyl, nitro, optionally substituted C_{1-6}-alkylthio,~~ and halogen, ~~where any C_{1-6} alkyl as an amino substiutent is optionally substituted with hydroxyl, C_{1-6}-alkoxy, amino, mono- and di(C_{1-6}-alkyl)amino, carboxy, C_{1-6}-alkylcarbonylamino, C_{1-6}-alkylaminocarbonyl, or halogen(s); and~~

~~or wherein R^1 and R^2 together with the carbon atoms to which they are attached form a heterocyclic ring, a heteroaromatic ring, an aromatic ring or a carbocyclic ring; and~~

with the proviso that R^1, R^2 and R^3 are not all hydrogen;

X^1 and X^2 are independently selected from hydroxy (-OH) and acetoxy (-OAc); and

pharmaceutically acceptable salts thereof.

26-28. (Cancelled)

29. (Previously presented) The method according to claim 1, wherein the method further comprises administering one or more other chemotherapeutic agents.

30-37. (Cancelled)

38. (Previously presented) The method according to claim 1, wherein both of X^1 and X^2 are hydroxyl (-OH).

39. (Previously presented) The use according to claim 1, wherein R^4 is hydrogen.

40. (Previously presented) The use according to claim 39, wherein R^3 and R^4 are both hydrogen.

41. (New) The method according to claim 1, wherein the compound is selected from the group consisting of:

1 5-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one,

2 5-fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

3 6-bromo-3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one,

4 6-bromo-7-ethyl-3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one,

5 6-bromo-5-ethyl-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one,

6 6-chloro-3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one,

7 6-chloro-7-ethyl-3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one,

8 6-chloro-5-ethyl-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one,

9 6-chloro-7-cyclopropyl-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

10 6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-trifluoromethyl-1,3-dihydro-indol-2-one,

11 acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-7-cyclopropyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester.

12 acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-2-oxo-7-trifluoromethyl-2,3-dihydro-1H-indol-3-yl]-phenyl ester,

13 6-chloro-4-fluoro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one,

14 acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-4-fluoro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester,

15 acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-4,7-dimethyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester,

16 6-Chloro-4,5-difluoro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one,

17 acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-4,5-difluoro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester,

18 3,3-Bis-(4-hydroxy-phenyl)-7-trifluoromethyl-1,3-dihydro-indol-2-one,

19 7-chloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

20 7-ethyl-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

21 3,3-bis-(4-hydroxy-phenyl)-7-isopropyl-1,3-dihydro-indol-2-one,

22 7-tert-butyl-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

23 7-bromo-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

24 7-ethyl-5-fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

25 3,3-bis-(4-hydroxy-phenyl)-5-iodo-1,3-dihydro-indol-2-one,

26 6-bromo-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one,

27 7-fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

28 4,7-dichloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

29 6-chloro-3,3-bis-(4-hydroxy-phenyl)-1,7-dimethyl-1,3-dihydro-indol-2-one,

30 3,3-bis-(4-hydroxy-phenyl)-4,7-dimethyl-1,3-dihydro-indol-2-one,

31 3,3-bis-(4-hydroxy-phenyl)-7-iodo-1,3-dihydro-indol-2-one,

32 acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester,

33 5,7-difluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

34 6-fluoro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one,

35 6,7-difluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

36 6-chloro-7-fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

37 5-fluoro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one,

38 6-fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one, and

39 7-chloro-6-fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one.